
	Where results make sense

Topic: Danaparoid

In the News (Thu 16 Feb 12)

EXECUTIVE POWER

Iran

ANALYSIS

Pakistan

Family compact

	Danaparoid
		Danaparoid sodium is an alternative anticoagulant in patients who develop heparin-induced thrombocytopenia (HIT) from heparin therapy.
		Ancrod represents a distinct anticoagulant that is derived from snake venom.
		Cross-reactivity of danaparoid with heparin-induced antibodies is less than 10% However, if after 48 hours following cessation of heparin and the initiation of danaparoid the platelets do not increase, the possibility of cross-reactivity should be considered and therapy switched to ancrod.
	www.amsect.org /ce/HIT/Danaparoid.htm (467 words)

	Rockingham Memorial Hospital (Site not responding. Last check: 2007-10-29)
		Danaparoid was approved for prophylaxis of post-operative DVT, which may lead to pulmonary embolism, in patients undergoing elective hip replacement surgery on 12/23/96.
		Pharmacokinetics: Danaparoid is administered by subcutaneous or intravenous injection.
		Danaparoid is primarily eliminated by the kidney, with renal excretion accounting for 40—50% of the total plasma clearance of anti-Xa activity.
	www.rmhonline.com /modules/goldstandard/monograph.asp?cpnum=698&name=Danaparoid (872 words)

	MedlinePlus Drug Information: Danaparoid (Systemic) (Site not responding. Last check: 2007-10-29)
		Danaparoid (da-NAP-a-roid) is used to prevent deep venous thrombosis, a condition in which harmful blood clots form in the blood vessels of the legs.
		Danaparoid is used for several days after hip replacement surgery, while you are unable to walk.
		Danaparoid also may be used for other conditions as determined by your doctor.
	www.nlm.nih.gov /medlineplus/druginfo/uspdi/203583.html (982 words)

	Pharmacy Update -- November/December 97 (Site not responding. Last check: 2007-10-29)
		Danaparoid is a mixture of glycosaminoglycans consisting of heparan sulfate (~84%), dermatan sulfate (~12%), and chondroitin sulfate (~4%) derived from porcine intestinal mucosa.
		Danaparoid is eliminated renally with a clearance of 0.36 L/h and a mean apparent volume of distribution of 8-9 L/kg.
		In the patients receiving 2000 units of danaparoid twice a day, there was a significant decrease in the incidence of recurrence or extension of thrombo-embolism (13%) compared to patients on continuous infusion of unfractionated heparin (28%).
	www.cc.nih.gov /phar/updates/97novdec.html (2173 words)

	DACC Danaparoid & Lepirudin (Site not responding. Last check: 2007-10-29)
		Danaparoid is derived from porcine intestinal mucosa and consists of 84% heparin sulfate, 12% dermatan sulfate, and 4% chondroitin sulfate.
		Danaparoid, like other anticoagulants, should be used with extreme caution in disease states in which there is increased risk of hemorrhage, such as severe uncontrolled hypertension, acute bacterial endocarditis, congenital or acquired bleeding disorders, active ulcerative and angiodysplastic gastrointestinal disease, non-hemorrhagic stroke, shortly after brain, spinal or ophthalmological surgery and post-operative indwelling epidural catheter use.
		Danaparoid should be considered the drug of choice for prophylaxis against DVT or PE in patients who have HIT type II and require systemic anticoagulation for prophylaxis (e.g., hip or knee replacement surgery) and do not have renal impairment.
	daccx.bsd.uchicago.edu /drug/bulletins/N0199.html (5660 words)

	Orgaran
		Danaparoid (da-NAP-a-roid) is used to prevent deep venous thrombosis, a condition in which harmful blood clots form in the blood vessels of the legs.
		Danaparoid is used for several days after hip replacement surgery, while you are unable to walk.
		Also, tell your doctor if you have received danaparoid before and had a reaction to it called thrombocytopenia (a low platelet count in the blood), or if new blood clots formed while you were receiving the medicine.
	www.healthtouch.com /bin/EContent_HT/drugShowLfts.asp?fname=usp0880.htm&title=Orgaran&cid=HT (1006 words)

	danaparoid
		There is a risk of bleeding in the spinal or epidural space, possibly resulting in paralysis, when danaparoid is used along with spinal or epidural anesthesia or spinal puncture.
		Danaparoid (Normiflo) is in the FDA pregnancy category B. This means that it is not likely to harm an unborn baby.
		Danaparoid must be used as a subcutaneous (under the skin) injection.
	hw.healthdialog.com /kbase/multum/d04114a1.htm (1375 words)

	Effect of danaparoid sodium on proteinuria, von Willebrand factor, and hard exudates in patients with diabetes mellitus ...
		Effect of danaparoid sodium on proteinuria, von Willebrand factor, and hard exudates in patients with diabetes mellitus type 2.In diabetic nephropathy, heparan sulfate glycosaminoglycan side chains are reduced in glomerular basement membranes proportionally to the degree of proteinuria.
		Recently, it was demonstrated that additional therapy with danaparoid sodium, a mixture of sulfated glycosaminoglycans with mainly heparan sulfate, lowered proteinuria in type 1 diabetes patients with diabetic nephropathy.
		The aim of the study was to evaluate the possible effects of danaparoid sodium on proteinuria, endothelial dysfunction, and hard exudates in the retina and to determine the safety/tolerability of this drug.
	www.pdg.cnb.uam.es /UniPub/iHOP/gp/1922300.html (298 words)

	PharmGKB: danaparoid (Site not responding. Last check: 2007-10-29)
		Danaparoid is indicated for the prevention of postoperative deep venous thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients undergoing elective hip replacement surgery.
		Danaparoid exhibits a low cross-reactivity with antiplatelet antibodies in individuals with Type II heparin-induced thrombocytopenia (HIT).
		Danaparoid prevents fibrin formation in the coagulation pathway by inhibiting thrombin generation through the inhibition of coagulation factor Xa and thrombin (factor IIa).
	www.pharmgkb.org /do/serve?objId=480&objCls=DrugProperties (601 words)

	Danaparoid feasible as heparin alternative in pregnant women
		German research suggests that danaparoid can be used as an alternative antithrombotic agent in heparin intolerant pregnant women with a high thrombotic risk.
		The initial doses of danaparoid varied from 1000 to 7500 U/day, and the median duration of use was 10 weeks.
		Of the remaining 14 pregnancies, danaparoid was stopped prematurely in nine cases due to suspected (n = 8) or confirmed (n = 1) cross-reactivity in four HIT and five non-HIT patients with skin rashes.
	www.incirculation.net /index.asp?did=18471&aid=44346&usechannel=THR (358 words)

	Danaparoid - Drugs & Vitamins - Drug Library - DrugDigest
		DANAPAROID (Orgaran™) was used to prevent clots in the veins, arteries, lungs, or heart during and after surgery.
		If you have been instructed to use danaparoid on a regular schedule, use missed doses as soon as you remember, unless it is almost time for the next dose.
		Keep danaparoid syringes in the refrigerator at a temperature between 2 degrees—8 degrees C (36 degrees—46 degrees F).
	www.drugdigest.org /DD/DVH/Uses/0,3915,6083\|Danaparoid,00.html (484 words)

	Danaparoid sodium
		Danaparoid sodium is an anti-clotting (anticoagulant) medicine belonging to a class of medicines called heparinoids.
		Danaparoid is given by injection or infusion and is used to prevent the formation of blood clots following surgery.
		Danaparoid has a lower potential of causing a reduction of platelets in the blood as compared to normal heparin.
	www.tiscali.co.uk /lifestyle/healthfitness/health_advice/netdoctor/archive/100003470.html (670 words)

	Heparin Antifactor Xa Assay
		If heparin (or LMWH or danaparoid) is present in the patient plasma, it will bind to antithrombin and inhibit factor Xa.
		Most of the time, LMWH and danaparoid antifactor Xa levels are in the appropriate range when specimens are drawn correctly.
		Occasions in which periodic monitoring of LMWH might be considered include renal failure, pregnancy (increased dosage requirement in the third trimester), pediatric patients (increased dosage requirement in newborns), obesity, underweight patients, prolonged use, or patients at high risk for bleeding or thrombosis.
	www.massgeneral.org /pathology/coagbook/co005000.htm (1064 words)

	Danaparoid in the prevention of thromboembolic complications -- Skoutakis 31 (7): 876 -- The Annals of Pharmacotherapy
		Danaparoid in the prevention of thromboembolic complications -- Skoutakis 31 (7): 876 -- The Annals of Pharmacotherapy
		CONCLUSIONS: Danaparoid is an antithrombotic agent with characteristics that distinguish it from heparin and LMWHs.
		Based on the efficacy and safety data reviewed, danaparoid should be considered one of the drugs of choice for the prevention of thromboembolic complications in patients undergoing orthopedic hip procedures and the drug of choice for the management of any patient with heparin-induced thrombocytopenia who requires anticoagulant therapy.
	www.theannals.com /cgi/content/abstract/31/7/876 (335 words)

	Danaparoid - Talk Medical
		This risk may be increased by the use of indwelling epidural catheters or by the concomitant use of drugs that affect blood clotting.
		· Before using Danaparoid, tell your doctor if you ·have bacterial endocarditis, ·have high blood pressure that is not being controlled, ·need to have surgery or another invasive procedure, ·have hemophilia or another blood disorder, ·have a stomach ulcer, ·have liver disease, or ·have kidney disease.
		Continue to use Danaparoid and notify your doctor if you experience ·mild pain, redness, or warmth at the injection site; ·rash or itching; ·fever; ·difficulty urinating; ·dizziness; ·nausea or vomiting; ·constipation; ·swelling or water retention; ·insomnia; or ·headache.
	www.talkmd.com /medications/print-1588 (879 words)

	Danaparoid (Systemic) - MayoClinic.com
		Danaparoid has not been studied in pregnant women.
		Studies on this medicine have been done only in adult patients, and there is no specific information comparing use of danaparoid in children with use in other age groups.
		The dose of danaparoid may be different for different patients.
	www.mayoclinic.com /health/drug-information/DR203583 (1005 words)

	Danaparoid (Subcutaneous Route) - MayoClinic.com
		Danaparoid is used to prevent deep venous thrombosis, a condition in which harmful blood clots form in the blood vessels of the legs.
		Danaparoid was available only with your doctor's prescription.
		Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate studies in pregnant women OR animal studies have shown an adverse effect, but adequate studies in pregnant women have failed to demonstrate a risk to the fetus.
	www.mayoclinic.com /health/drug-information/DR600517 (1166 words)

	Heparin Antifactor Xa Assay (Site not responding. Last check: 2007-10-29)
		In fact, if a LMWH or danaparoid antifactor Xa level is subtherapeutic, the most common causes are drawing the specimen at the wrong time (see below) or specimen transportation was longer than 2 hours.
		Most of the time, LMWH and danaparoid antifactor Xa levels are in the appropriate range when specimens are drawn correctly.
		Occasions in which periodic monitoring of LMWH might be considered include renal failure, pregnancy (increased dosage requirement in the third trimester), pediatric patients (increased dosage requirement in newborns), obesity, underweight patients, prolonged use, or patients at high risk for bleeding or thrombosis.
	www.mgh.harvard.edu /labmed/lab/coag/handbook/CO005000.htm (1064 words)

	Successful use of danaparoid in treatment of heparin-induced thrombocytopenia during twin pregnancy -- Gill and Kovacs ...
		Treatment was initiated with danaparoid by subcutaneous injection and was continued until the time of delivery.
		CONCLUSION: Danaparoid, which has low cross-reactivity for heparin-dependent antibodies and no known fetopathic effects, was used successfully to treat our patient, who developed heparin-induced thrombocytopenia during pregnancy.
		Danaparoid may be the treatment of choice for this difficult clinical situation in which there are limited therapeutic options.
	www.greenjournal.org /cgi/content/abstract/90/4/648 (231 words)

	danaparoid Information and Resources Online at The Drug Database - Find Useful Articles and Websites on danaparoid ...
		Danaparoid (da-NAP-a-roid) is used to prevent deep venous thrombosis, a condition in which harmful...
		Danaparoid is used for several days after hip...
		it was demonstrated that additional therapy with danaparoid sodium, a mixture of sulfated glycosaminoglycans with mainly...
	www.thedrugdatabase.com /directory/D/danaparoid (344 words)

	Efficacy and Safety of Danaparoid Sodium (ORG 10172) in Critically Ill Patients With Heparin-Associated ...
		the persistence or the recurrence of thrombocytopenia in danaparoid
		danaparoid sodium molecule was observed in 3 of 46 patients
		Chong, BH, Magnani, HN (1992) Danaparoid sodium in heparin-induced thrombocytopenia.
	www.chestjournal.org /cgi/content/full/115/6/1616 (2568 words)

	AJC Health : Integrative Medicine : Drugs : Danaparoid \| ajc.com
		If you have an allergy to pork, danaparoid, or any other part of the medicine.
		If you have any of the following conditions: Low platelet count with another use of danaparoid, active bleeding, or are a bleeder.
		Danaparoid thins the blood by changing the body's clotting system.
	www.ajc.com /health/altmed/shared/health/alt_medicine/ConsDrugs/Danaparoidcd.html (599 words)

	DANAPAROID FOR DVT - Journal Watch (General)
		This multicenter, randomized trial from the Netherlands compared heparin with danaparoid -- a mixture of low-molecular-weight heparan sulfate, dermatan sulfate, and chondroitin sulfate that has no effect on platelet function.
		After five to eight days, the patients given high-dose (but not low-dose) danaparoid had significantly less recurrence or extension of venous thromboembolism than the heparin group (13 vs. 28 percent) and less recurrent pulmonary embolism (7 vs. 24 percent).
		Comment: These findings suggest that danaparoid may be a useful alternative to standard heparin for DVT.
	general-medicine.jwatch.org /cgi/content/full/1995/707/1 (226 words)

	Deep vein thrombosis: danaparoid was not clearly better than heparin.
		Deep vein thrombosis: danaparoid was not clearly better than heparin.
		In patients with deep venous thrombosis or pulmonary embolism, danaparoid was not clearly as effective as unfractionated heparin in preventing recurrences.
		Danaparoid is thought to cause less thrombocytopenia than heparin (based on animal studies).
	www.eboncall.org /CATs/1815.htm (211 words)

	Danaparoid
		Consider risk versus benefit prior to neuraxial anesthesia; risk is increased by concomitant agents which may alter hemostasis, as well as traumatic or repeated epidural or spinal puncture.
		As with all anticoagulants, bleeding is the major adverse effect of danaparoid.
		A 750 anti-Xa unit dose of danaparoid is approximately equivalent to 55 mg of danaparoid.
	www.metagenics.com /ADAM/41/035075.html (914 words)

	Danaparoid (Systemic) - New Jersey
		Danaparoid has not been studied in pregnant women.
		Studies on this medicine have been done only in adult patients, and there is no specific information comparing use of danaparoid in children with use in other age groups.
		Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur.
	www.somersetmedicalcenter.com /15900.cfm (1064 words)

	Heparin versus danaparoid in off-pump coronary bypass grafting: Results of a prospective randomized clinical trial -- ...
		Heparin versus danaparoid in off-pump coronary bypass grafting: Results of a prospective randomized clinical trial -- Carrier et al.
		Heparin versus danaparoid in off-pump coronary bypass grafting: Results of a prospective randomized clinical trial
		danaparoid, and 37 patients underwent 2.5 ± 0.9 grafts
	jtcs.ctsnetjournals.org /cgi/content/abstract/125/2/325 (446 words)

	American Family Physician : Ardeparin and danaparoid for prevention of DVT. (deep venous thrombosis)(Tips from Other ... (Site not responding. Last check: 2007-10-29)
		Without anticoagulation prophylaxis, deep venous thrombosis occurs in up to 30 percent of patients after abdominal surgery and in 40 to 70 percent of patients after major orthopedic surgery on the lower limbs.
		Ardeparin sodium, a low-molecular-weight heparin, and danaparoid sodium, a heparinoid, have received approval from the U.S. Food and Drug Administration for use in the prevention of deep venous thrombosis.
		Danaparoid is approved in the United States only for use in patients who have had hip replacement, and ardeparin is approved only for use in those who have had knee replacement.
	static.elibrary.com /a/americanfamilyphysician/march011998/ardeparinanddanaparoidforpreventionofdvtdeepvenous/index.html (239 words)

	Health Library - (Site not responding. Last check: 2007-10-29)
		These medicines may lead to bleeding when taken with danaparoid.
		Danaparoid is used to prevent blood clot formation following hip replacement surgery.
		Other less serious side effects may be more likely to occur.
	www.stjosepheureka.org /library/healthguide/en-us/drugguide/topic.asp?hwid=d04114a1 (1294 words)

Try your search on: Qwika (all wikis)